Immutep (IMMP) shares were up more than 11% in recent Thursday trading after the company reported positive data from the phase 1 trial evaluating eftilagimod alpha, also known as efti, in combination with Keytruda and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.
The company said the trial's overall survival and progression-free survival data, with a minimum follow-up of almost two years, exceeded expectations and all evaluable patients to date also demonstrated "significant improvement" in overall response rate.
The combination therapy also continued to demonstrate a favorable safety profile, Immutep added.
Immutep said the phase 1 trial is nearing the completion of its patient enrollment, with additional data updates expected in 2025.
Price: 2.08, Change: +0.21, Percent Change: +11.23
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。